Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging strategies to target RAS signaling in human cancer therapy
Kun Chen, Yalei Zhang, Ling Qian, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 158

Showing 1-25 of 158 citing articles:

Senescence and cancer — role and therapeutic opportunities
Clemens A. Schmitt, Boshi Wang, Marco Demaria
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 619-636
Open Access | Times Cited: 433
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Md Entaz Bahar, Hyun Joon Kim, Deok Ryong Kim
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 224
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers
Hong‐Beom Park, Kwang‐Hyun Baek
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188736-188736
Closed Access | Times Cited: 95
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 23
Variant reclassification and clinical implications
Nicola Walsh, Aislinn Cooper, Adrian Dockery, et al.
Journal of Medical Genetics (2024) Vol. 61, Iss. 3, pp. 207-211
Open Access | Times Cited: 22
Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy
Weirong Qin, Zijian Liu, Mingyu Huang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1425-1425
Open Access | Times Cited: 2
RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics
Poonam R. Pandey, Ken H. Young, Dhiraj Kumar, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 59
Ferroptosis and EMT: key targets for combating cancer progression and therapy resistance
Yuqing Ren, Xiangrong Mao, Hui Xu, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 9
Open Access | Times Cited: 31
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
A Potential “Anti-Warburg Effect” in Circulating Tumor Cell-mediated Metastatic Progression?
Zhuofeng Jiang, Jiapeng He, Binyu Zhang, et al.
Aging and Disease (2024)
Open Access | Times Cited: 14
STK19 is a DNA/RNA-binding protein critical for DNA damage repair and cell proliferation
Y Li, Yanqiu Gong, Yue Zhou, et al.
The Journal of Cell Biology (2024) Vol. 223, Iss. 2
Open Access | Times Cited: 12
Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit
Yuanjiang Wang, Jianluo Zhang, Kun Li, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 3, pp. 2066-2082
Closed Access | Times Cited: 8
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Zixi Wang, Yurou Xing, Bingjie Li, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 31
RAS degraders: The new frontier for RAS-driven cancers
Taylor E. Escher, K.J.F. Satchell
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1904-1919
Open Access | Times Cited: 19
Therapeutic strategies targeting AMPK-dependent autophagy in cancer cells
Wenbin Yuan, Wanyi Fang, Rui Zhang, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2023) Vol. 1870, Iss. 7, pp. 119537-119537
Closed Access | Times Cited: 19
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
Harnessing the potential of CD40 agonism in cancer therapy
Yang Zhou, Ann Richmond, Chi Yan
Cytokine & Growth Factor Reviews (2023) Vol. 75, pp. 40-56
Open Access | Times Cited: 16
Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery
Jialin Wu, Xiaoxue Li, Chengyong Wu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116282-116282
Closed Access | Times Cited: 6
Impact of Systemic Treatments on Outcomes and Quality of Life in Patients with RAS-Positive Stage IV Colorectal Cancer: A Systematic Review
Vlad Braicu, S. Pantea, Fulger Lazăr, et al.
Diseases (2024) Vol. 12, Iss. 4, pp. 79-79
Open Access | Times Cited: 6
Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine
Kai‐Bo Wang, Yushuang Liu, Jinzhu Li, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 27
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
Yuqing Lu, Yuewen Yang, Guanghao Zhu, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 11, pp. 3360-3382
Open Access | Times Cited: 14
Therapeutic strategies targeting cellular senescence for cancer and other diseases
Xuebing Wang, Takeshi Fukumoto, Ken-ichi Noma
The Journal of Biochemistry (2024) Vol. 175, Iss. 5, pp. 525-537
Open Access | Times Cited: 5
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
High Pressure Promotes Binding of the Allosteric Inhibitor Zn2+‐Cyclen in Crystals of Activated H‐Ras
Éric Girard, Pedro Lopes, Michael Spoerner, et al.
Chemistry - A European Journal (2024) Vol. 30, Iss. 35
Closed Access | Times Cited: 4
Natural products targeting RAS by multiple mechanisms and its therapeutic potential in cancer: An update since 2020
Yanqing Liu, Jie Chen, Xiang Li, et al.
Pharmacological Research (2025) Vol. 212, pp. 107577-107577
Open Access
Page 1 - Next Page

Scroll to top